Ethical issues concerning therapeutic studies in inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 13, Issue 9, 2007, Pages 1141-1145

  Tremaine, William J ^a   Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

Conflict of interest; Crohn's disease; Equipoise; Ethics; Inflammatory bowel disease; Therapeutic misconception; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; PREDNISONE;

CLINICAL ASSESSMENT; CLINICAL RESEARCH; CLINICAL TRIAL; COMORBIDITY; CROHN DISEASE; DECISION MAKING; DOCTOR PATIENT RELATION; FINANCIAL MANAGEMENT; HEALTH CARE; HEALTH SERVICE; HUMAN; MEDICAL ETHICS; MEDICAL PRACTICE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; ULCERATIVE COLITIS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CONFLICT OF INTEREST; CROHN DISEASE; ETHICS COMMITTEES, RESEARCH; ETHICS, MEDICAL; HUMAN EXPERIMENTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; INFORMED CONSENT; TESTOSTERONE;

EID: 34548653697     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20133     Document Type: Review

References (25)

1. Gurmankin AD, Baron J, Hershey JC, Ubel PA. The role of physicians' recommendations in medical treatment decisions. Med Decis Making. 2002;22:262-271.
2. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;2:1041-1048.
3. The Belmont Report: ethical principles and guidelines for the protection of human subjects of research. In: Research NCftPoHRSoBaB, ed. DHEW (OS) 78-0013 and (OS) 78-0014.4. Volume 2007. Washington, DC: U.S. Government Printing Office; 1979.
4. Ethical principles for medical research involving human subjects. In: Helsinski WMADo, ed. Volume 2007. Helsinki, Finland; 1964.
5. Appelbaum PS, Roth LH, Lidz CW, Benson P, Winslade W. False hopes and best data: consent to research and the therapeutic misconception. Hastings Cent Rep. 1987;17:20-24.
6. Conn HO. Transjugular intrahepatic portosystemic shunts versus sclerotherapy: a discussion of discordant results. Ann Intern Med. 1997;126: 907-910.
7. Madsen SM, Holm S, Davidsen B, Munkholm P, Schlichting P, Riis P. Ethical aspects of clinical trials: the attitudes of participants in two non-cancer trials. J Intern Med. 2000;248:463-474.
8. Morin K, Rakatansky H, Riddick FA Jr, et al. Managing conflicts of interest in the conduct of clinical trials. JAMA. 2002;287:78-84.
9. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research participation. N Engl J Med. 1999;341:198-203.
10. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
11. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
12. Hommes D, Baert F, van Assche G, et al. The ideal management of Crohn's disease: top down versus step up strategies: a randomized controlled trial [Abstract]. Gastroenterology. 2006;130:A108.
13. Brown A, Kraft D, Schmitz SM, et al. Association of industry sponsorship to published outcomes in gastrointestinal clinical research. Clin Gastroenterol Hepatol. 2006;4:1445-1451.
14. Bodenheimer T. Uneasy alliance - clinical investigators and the pharmaceutical industry. N Engl J Med. 2000;342:1539-1544.
15. Steinbrook R. Wall Street and clinical trials. N Engl J Med. 2005;353: 1091-1093.
16. Weinfurt KP, Friedman JY, Dinan MA, et al. Disclosing conflicts of interest in clinical research: views of institutional review boards, conflict of interest committees, and investigators. J Law Med Ethics. 2006;34: 581-591.
17. Steinbrook R. Financial conflicts of interest and the Food and Drug Administration's Advisory Committees. N Engl J Med. 2005;353:116-118.
18. Camilleri M. Doctors, AGA, and industry: steps toward improving the relationship. Clin Gastroenterol Hepatol. 2006;4:160-166.
19. The Bayh-Dole Act. P.L. 96-517, Patent and Trademark Act Amendments of 1980. Volume 2007. The Association of University Technology Managers; 1980.
20. Camilleri M, Gamble GL, Kopecky SL, Wood MB, Hockema ML. Principles and process in the development of the Mayo Clinic's individual and institutional conflict of interest policy. Mayo Clin Proc. 2005;80:1340-1346.
21. Slutsky AS, Lavery JV. Data safety and monitoring boards. N Engl J Med. 2004;350:1143-1147.
22. Campbell EG, Weissman JS, Vogeli C, et al. Financial relationships between institutional review board members and industry. N Engl J Med. 2006;355:2321-2329.
23. Lurie P, Almeida CM, Stine N, Stine AR, Wolfe SM. Financial conflict of interest disclosure and voting patterns at Food and Drug Administration Drug Advisory Committee meetings. JAMA. 2006;295:1921-1928.
24. Hampson LA, Agrawal M, Joffe S, Gross CP, Verter J, Emanuel EJ. Patients' views on financial conflicts of interest in cancer research trials. N Engl J Med. 2006;355:2330-2337.
25. Levinsky NG. Nonfinancial conflicts of interest in research. N Engl J Med. 2002;347:759-761.